Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
about
Nitrate in the active site of protein tyrosine phosphatase 1B is a putative mimetic of the transition stateWhy Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical ReviewMolecular mechanisms of chromium in alleviating insulin resistanceDesign, synthesis and pharmacological evaluation of novel vanadium-containing complexes as antidiabetic agentsCyclooxygenase-1 as the main source of proinflammatory factors after sodium orthovanadate treatmentHD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain.Molecular regulation of tumor angiogenesis and perfusion via redox signaling.Identification of a potent activator of Akt phosphorylation from a novel series of phenolic, picolinic, pyridino, and hydroxamic zinc(II) complexes.The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.The need for combined inorganic, biochemical, and nutritional studies of chromium(III).Biotransformations of Antidiabetic Vanadium Prodrugs in Mammalian Cells and Cell Culture Media: A XANES Spectroscopic Study.Vanadium and the cardiovascular functions.Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies.Functional role of inorganic trace elements in angiogenesis part III: (Ti, Li, Ce, As, Hg, Va, Nb and Pb).Metal-based anti-diabetic drugs: advances and challenges.Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant miceCharacterisation of the PTEN inhibitor VO-OHpicAntidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.Synthesis and evaluation of oxovanadium(IV) complexes of Schiff-base condensates from 5-substituted-2-hydroxybenzaldehyde and 2-substituted-benzenamine as selective inhibitors of protein tyrosine phosphatase 1B.A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding.A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors.Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.Vanadium Compounds as PTP Inhibitors.Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates.Influence of Feeding Inorganic Vanadium on Growth Performance, Endocrine Variables and Biomarkers of Bone Health in Crossbred Calves.Inhibition of protein tyrosine phosphatases enhances cerebral collateral growth in rats.Biochemical MechanismsMetal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and LigandsExploration of biguanido–oxovanadium complexes as potent and selective inhibitors of protein tyrosine phosphatasesVanadium(IV) and -(V) Complexes of Reduced Schiff Bases Derived from Aromatic o-Hydroxyaldehydes and Tyrosine Derivatives
P2860
Q27689095-6CA22243-FAAE-4C2D-864F-420A439C96F5Q28068342-FD26CBF1-6D01-4F6D-860D-1C00A3F6F648Q28262068-1B0AC5AE-5BC0-42B9-A44E-5CD3A391F085Q28541137-11B246B8-FA50-48EF-AA54-5320D13BCC9AQ28652149-7BA6E50C-C47A-43D6-AF59-7340E669E821Q33425933-11B3A3FF-DC27-4F28-8564-CF830DB8A3AFQ33572306-4403527A-3487-4BA2-8FEE-1086873E4CEBQ33726915-EB84658C-0C17-45E5-B593-D60F3B7528FCQ34262663-05B8C108-8F05-4E1F-9111-80FBFAB93AF9Q34299674-4DCE2A65-7F43-4279-A5EE-5D27BE75885DQ35612899-0FF1A4B6-32DE-4099-9C25-2D77447AA586Q35968505-D9516A18-B6D1-4ECB-8BA6-E694BDB4925DQ36271101-F574122A-A438-4524-82A5-2985131D8FBCQ37576114-8BBC7681-B3D7-44FE-B559-CCF806B05B48Q37900507-8FBF3455-0737-4743-ABCC-FE9BCA6D7A75Q39065291-473C8488-D4A3-4BBC-A107-E6D3C269E237Q39742541-F86CAFA8-C21D-4ACD-AF8F-BA87CFCF8028Q42582786-CC348E17-31FD-4205-880F-0036742532FFQ42716649-562D3456-737B-442A-A5D2-DA143A748681Q44206373-DD84358F-B38C-496A-8DCF-255A487A641AQ44504229-74F8004F-DBD5-46EE-9C87-81D6E741FB51Q44779130-AA8E1C7B-DD74-4AC7-AF4A-C1A2DF808DFCQ47276971-3BD38802-7BBE-4575-9806-16C09F843202Q47602319-3C2D3DA5-763A-4E91-8151-ABD95EE5A2CCQ48361524-FBDBBF66-CDA2-4A13-9380-FDA48E5160E1Q48770173-1A8B4D1E-B40F-4F77-A802-C1BCD7689F32Q57602266-3E2DA958-98EB-43E7-BE9F-4FFA5144C42BQ57693525-E2E65575-03D4-4E95-9472-C9F7521ADFF1Q57752730-30EE7014-6C29-4EA2-8C32-13A85D48FE6AQ59083004-453D143A-B40B-47F9-A2B2-F03A6FAEEED5
P2860
Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Mechanism of insulin sensitiza ...... (VO4) as the active component.
@en
Mechanism of insulin sensitization by BMOV
@nl
type
label
Mechanism of insulin sensitiza ...... (VO4) as the active component.
@en
Mechanism of insulin sensitization by BMOV
@nl
prefLabel
Mechanism of insulin sensitiza ...... (VO4) as the active component.
@en
Mechanism of insulin sensitization by BMOV
@nl
P2093
P1476
Mechanism of insulin sensitiza ...... (VO4) as the active component.
@en
P2093
Artem Evdokimov
Brian W Howard
Conrad Diven
Elaine Eby-Wilkens
Frank Genbauffe
Kevin G Peters
Matthew Maier
Matthew Pokross
Mike G Davis
Shari Soper
P304
P356
10.1016/S0162-0134(03)00236-8
P577
2003-08-01T00:00:00Z